[go: up one dir, main page]

WO2024216007A3 - Pd-1/tigit binding proteins for cancer treatment - Google Patents

Pd-1/tigit binding proteins for cancer treatment Download PDF

Info

Publication number
WO2024216007A3
WO2024216007A3 PCT/US2024/024236 US2024024236W WO2024216007A3 WO 2024216007 A3 WO2024216007 A3 WO 2024216007A3 US 2024024236 W US2024024236 W US 2024024236W WO 2024216007 A3 WO2024216007 A3 WO 2024216007A3
Authority
WO
WIPO (PCT)
Prior art keywords
binding proteins
cancer treatment
tigit binding
tigit
bind
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
PCT/US2024/024236
Other languages
French (fr)
Other versions
WO2024216007A2 (en
Inventor
Moritz DRACHSLER
KyoungSoo LIM
Chang GONG
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MedImmune LLC
Original Assignee
MedImmune LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by MedImmune LLC filed Critical MedImmune LLC
Priority to AU2024251844A priority Critical patent/AU2024251844A1/en
Publication of WO2024216007A2 publication Critical patent/WO2024216007A2/en
Publication of WO2024216007A3 publication Critical patent/WO2024216007A3/en
Priority to IL323643A priority patent/IL323643A/en
Anticipated expiration legal-status Critical
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

The disclosure relates to methods of treating cancer by administering binding proteins, including antibodies, that bind to Programmed Death-1 ("PD-1") and T cell immunoreceptor with Ig and ITIM domains ("TIGIT") to a subject in an amount from about 70 mg to about 1500 mg.
PCT/US2024/024236 2023-04-13 2024-04-12 Pd-1/tigit binding proteins for cancer treatment Pending WO2024216007A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU2024251844A AU2024251844A1 (en) 2023-04-13 2024-04-12 Pd-1/tigit binding proteins for cancer treatment
IL323643A IL323643A (en) 2023-04-13 2025-09-28 Pd-1/tigit binding proteins for cancer treatment

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202363495837P 2023-04-13 2023-04-13
US63/495,837 2023-04-13
US202363592164P 2023-10-21 2023-10-21
US63/592,164 2023-10-21

Publications (2)

Publication Number Publication Date
WO2024216007A2 WO2024216007A2 (en) 2024-10-17
WO2024216007A3 true WO2024216007A3 (en) 2025-02-27

Family

ID=93060270

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2024/024236 Pending WO2024216007A2 (en) 2023-04-13 2024-04-12 Pd-1/tigit binding proteins for cancer treatment

Country Status (5)

Country Link
US (1) US20240392005A1 (en)
AU (1) AU2024251844A1 (en)
IL (1) IL323643A (en)
TW (1) TW202506180A (en)
WO (1) WO2024216007A2 (en)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20180022807A1 (en) * 2016-05-06 2018-01-25 Medimmune, Llc Bispecific binding proteins and uses thereof
US20220411509A1 (en) * 2021-04-30 2022-12-29 Medimmune, Llc Bispecific pd-1 and tigit binding proteins and uses therof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20180022807A1 (en) * 2016-05-06 2018-01-25 Medimmune, Llc Bispecific binding proteins and uses thereof
US20220411509A1 (en) * 2021-04-30 2022-12-29 Medimmune, Llc Bispecific pd-1 and tigit binding proteins and uses therof

Also Published As

Publication number Publication date
IL323643A (en) 2025-11-01
US20240392005A1 (en) 2024-11-28
TW202506180A (en) 2025-02-16
AU2024251844A1 (en) 2025-10-09
WO2024216007A2 (en) 2024-10-17

Similar Documents

Publication Publication Date Title
DE4337197C1 (en) Process for the selective preparation of hybridoma cell lines which produce monoclonal antibodies with high cytotoxicity against human CD16 antigen, and the preparation of bispecific monoclonal antibodies using such monoclonal antibodies and the CD30-HRS-3 antibody for therapy of human tumours
KR890015751A (en) Antibody Heteroconjugates Useful for Modulating Lymphocyte Activity
IL265541B2 (en) Bispecific antibodies and compositions comprising thereof for treating cancer
IL278633B2 (en) Immunoconjugates
SG138469A1 (en) Antibodies to insulin-like growth factor i receptor
GB9009548D0 (en) Chimeric antibody and method
MXPA06003788A (en) Fully human antibodies against human 4-1bb (cd137).
NO20053417L (en) Human monoclonal antibodies to interleukin 8 (IL-8)
RU2007145419A (en) MONOCLONAL HUMAN ANTIBODIES TO PROGRAMMABLE DEATH PROTEIN 1 (PD-1) AND METHODS OF TREATING CANCER USING ANTI-PD-1 ANTIBODIES INDEPENDENTLY OR IN COMBINATION WITH OTHER IMPORTANCE
WO2004010947A3 (en) Humanized antibodies against human 4-1bb
DE69125485T2 (en) METHOD AND INTERMEDIATE PRODUCTS OF SYNTHETIC ANTIBODY DERIVATIVES
WO2022229919A3 (en) Bispecific pd-1 and tigit binding proteins and uses therof
DE4421391C1 (en) Use of antibodies against T cells for prolonged immunosuppression
WO2008100563A3 (en) Compositions and methods for diagnosing and treating cancer
EP2428216A3 (en) Methods of treating cancer using IL-21 and monoclonal antibody therapy
WO2021074695A8 (en) PD-L1 INHIBITOR - TGFβ INHIBITOR BISPECIFIC DRUG MOIETIES.
WO2024216007A3 (en) Pd-1/tigit binding proteins for cancer treatment
MX2023008597A (en) Methods of cancer treatment using anti-tigit antibodies in combination with anti-pd1 antibodies.
WO2024173607A3 (en) Combination of bispecific antibodies and chimeric antigen receptor t cells for treatment
CA3224180A1 (en) Methods and compositions for treating cancer
MX2024002961A (en) Antibody and use thereof.
WO2024173830A3 (en) Induced nk cells responsive to cd3/taa bispecific antibodies
DK1165615T3 (en) Monoclonal antibodies to human protein Mcm3, process for their preparation of their use
WO2016124512A1 (en) Antigen-binding constructs, namely single domain vhh fragments which bind to and inhibit catalase and/or superoxide dismutase as well as pharmaceutical compositions containing them for tumor therapy
WO1994024163A3 (en) Bispecific antigen-binding molecules

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 24789517

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: AU2024251844

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 323643

Country of ref document: IL

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112025020923

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 2024251844

Country of ref document: AU

Date of ref document: 20240412

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: P2025-03241

Country of ref document: AE

WWE Wipo information: entry into national phase

Ref document number: 202592761

Country of ref document: EA

WWE Wipo information: entry into national phase

Ref document number: KR1020257037614

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 2024789517

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2024789517

Country of ref document: EP

Effective date: 20251113

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 24789517

Country of ref document: EP

Kind code of ref document: A2